AIM： To determine whether glaucoma patients exhibit an abnormal melatonin concentration in serum and the effects of psychiatric disorders caused by glaucoma in melatonin secretion.METHODS： A sample of 80 primary ang...AIM： To determine whether glaucoma patients exhibit an abnormal melatonin concentration in serum and the effects of psychiatric disorders caused by glaucoma in melatonin secretion.METHODS： A sample of 80 primary angle-closure glaucoma（PACG） patients, 120 primary open angle glaucoma（POAG） patients, and 120 normal controls were enrolled in this study. All the participants were asked to complete the following questionnaires： Pittsburgh sleep quality index（PSQI）, self-rating anxiety scale（SAS）, and self-rating depression scale（SDS）. Variance analysis was used to compare the subscores between the groups. After that, we chose 58 patients with primary glaucoma and 20 nonglaucoma control patients to collect their serum samples at 7-10 a.m. Serum melatonin levels were measured using enzyme linked immunosorbent assay（ELISA）. RESULTS： Of all participants, the scores of PSQI, SAS, and SDS in PACG and POAG group were 9.38±0.40, 46.08±8.99, 51.11±10.72 and 7.43±0.35, 45.42±9.87, 49.04±12.24 respectively, significantly higher than those in control group（4.16±0.28, 35.49±9.18, 40.31±13.08）. The serum melatonin levels in PACG（37.29±2.99 pg/mL） and POAG（35.97±3.64 pg/mL） were significantly higher than the controls（29.96±3.94 pg/m L）（P〈0.001）. But no difference was found between the PACG and POAG（P=0.216）. Glaucoma patients with sleep disorders, anxiety and depression were more likely resulting in the increase of melatonin levels.CONCLUSION： There is a significant increase in serum melatonin levels in glaucoma patients compared to the controls especially in glaucoma patients with psychiatric disorders such as sleep disorders, anxiety and depression.展开更多
文摘AIM： To determine whether glaucoma patients exhibit an abnormal melatonin concentration in serum and the effects of psychiatric disorders caused by glaucoma in melatonin secretion.METHODS： A sample of 80 primary angle-closure glaucoma（PACG） patients, 120 primary open angle glaucoma（POAG） patients, and 120 normal controls were enrolled in this study. All the participants were asked to complete the following questionnaires： Pittsburgh sleep quality index（PSQI）, self-rating anxiety scale（SAS）, and self-rating depression scale（SDS）. Variance analysis was used to compare the subscores between the groups. After that, we chose 58 patients with primary glaucoma and 20 nonglaucoma control patients to collect their serum samples at 7-10 a.m. Serum melatonin levels were measured using enzyme linked immunosorbent assay（ELISA）. RESULTS： Of all participants, the scores of PSQI, SAS, and SDS in PACG and POAG group were 9.38±0.40, 46.08±8.99, 51.11±10.72 and 7.43±0.35, 45.42±9.87, 49.04±12.24 respectively, significantly higher than those in control group（4.16±0.28, 35.49±9.18, 40.31±13.08）. The serum melatonin levels in PACG（37.29±2.99 pg/mL） and POAG（35.97±3.64 pg/mL） were significantly higher than the controls（29.96±3.94 pg/m L）（P〈0.001）. But no difference was found between the PACG and POAG（P=0.216）. Glaucoma patients with sleep disorders, anxiety and depression were more likely resulting in the increase of melatonin levels.CONCLUSION： There is a significant increase in serum melatonin levels in glaucoma patients compared to the controls especially in glaucoma patients with psychiatric disorders such as sleep disorders, anxiety and depression.
